Dr. Salman Fazal Recognized as 2026 Castle Connolly Top Doctor for Excellence

Salman Fazal, MD, has achieved the prestigious distinction of being named a 2026 Castle Connolly Top Doctor for the third consecutive year. This honor recognizes the top seven percent of licensed physicians nationwide, highlighting Dr. Fazal’s exceptional expertise in hematology and cellular therapy. Based at the UPMC Hillman Cancer Center, he specializes in treating complex malignant hematologic conditions, including leukemia, lymphoma, and multiple myeloma, while prioritizing a compassionate, patient-centered approach to oncology.

With over 16 years of clinical experience, Dr. Fazal leads the bispecific therapy program in Central Pennsylvania. His career is defined by transformative leadership, notably turning around transplant survival rates and spearheading advanced treatments such as CAR-T and hematopoietic stem cell transplantation. His commitment to innovation ensures that patients facing high-risk, refractory diseases have access to cutting-edge clinical research and life-saving therapeutic options that extend beyond conventional medical standards.

Beyond his clinical work, Dr. Fazal is a dedicated educator and researcher whose findings have appeared in The New England Journal of Medicine and The Lancet. As a board-certified specialist and award-winning teacher, he continues to shape the future of hematology. His ongoing contributions to the Leukemia & Lymphoma Society and his focus on long-term patient outcomes solidify his reputation as a national leader in cancer care and medical education.